Noncash interest expense (including related party amounts of 237 and 698 for the three months ended march 31, 2025 and 2024, respectively)
403
Gain on amendments to financial instruments, net
0
Loss on issuance of financial instruments (including related party amounts of zero and 74 for the three months ended march 31, 2025 and 2024, respectively)
-1,050
Change in fair value of financial instruments (including related party amounts of 1,041 and zero for the three months ended march 31, 2025 and 2024, respectively)
21,575
Loss on sale of property and equipment, net
0
Prepaid expenses and other current assets
128
Accounts payable and accrued expenses
1,079
Other current liabilities
-25
Operating lease liability
-40
Other, net
0
Net cash used in operating activities
-2,800
Sales of property and equipment
0
Purchases of capitalized software
52
Net cash (used in) provided by investing activities
-52
Proceeds from amendment to and settlements of fpa agreements
0
Proceeds-Convertible12Promissory Notes
1,800
Proceeds-Convertible Bridge Loans
90
Proceeds from issuance of bridge notes
0
Proceeds from amendment to the pipe warrants
0
Proceeds from conversion of warrants to common stock
11
Proceeds from capital contributions
1,745
Payment of revolving line of credit
1,000
Payment of transaction costs
0
Proceeds from repayments of receivables from shareholder
0
Net cash provided by financing activities
2,646
Net (decrease) increase in cash, cash equivalents, and restricted cash
-206
Cash and cash equivalents at beginning of period
235
Cash and cash equivalents at end of period
29
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.